---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-200272"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:15:48.736301+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaccinex reports pepinemab slows cognitive decline in MCI due to AD; plans partnership

## Summary
- Pepinemab showed significant reduction in brain metabolic decline (FDG-PET) in medial temporal cortex (p=0.0297) vs placebo.
- In MCI patients, reduced astrocyte reactivity (GFAP) and neuronal damage marker p-tau217; no effect in early dementia.
- Cognitive decline slowed in MCI per iADRS and ADAS-Cog13; no benefit in early dementia group.
- Company plans to pursue a development partnership to reduce operating expenses going forward.
- Pepinemab was well-tolerated, consistent with prior Huntington's disease studies.

## SEC filing metadata
- accession: 0001193125-24-200272
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312524200272/0001193125-24-200272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312524200272/d838109d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-200272
- JSON: https://secwatch.observer/filing/0001193125-24-200272.json
- Plain text: https://secwatch.observer/filing/0001193125-24-200272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.